UZEDY ER 75 MG/0.21 ML SYRINGE

What it is

UZEDY ER 75 MG/0.21 ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as risperidone, under the trade name “UZEDY”.

FDA gives its dosage form as injection, suspension, extended release and its route as subcutaneous.

The labeler, the company named on the label, is Teva Pharmaceuticals USA, Inc.

FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 51759-0410-10.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1,965.32 for 0.21 mL (0.21 × $9,358.65986 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

• 51759-0410-10 · Teva Pharmaceuticals USA, Inc. · $9,358.65986 per ML · eff. 2026-09-23 filed

Other strengths, forms and brands

30 other products in the NADAC file share the FDA nonproprietary name risperidone with UZEDY ER 75 MG/0.21 ML SYRINGE. The 23 below share a strength or dosage form with it first; search OpenBill for the rest.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

Its NADAC price is $9,358.65986 per ML filed.

Of the 25 other products in FDA’s Atypical Antipsychotic class priced per ML, 2 have a higher middle NADAC price and 23 a lower one. The one in the middle is INVEGA SUSTENNA 234 MG/1.5 ML, at $2,338.47458 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J2799, for 2026-10-01 to 2026-12-31, comes to $1,967.03 for 0.21 mL, or $9,366.78571 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $5.2454 per 1 MG.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 0.21 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 0.21 mL; your package may hold a different amount.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.